FDA and EMA chief medical officers don’t expect ChatGPT to help with drug reviews anytime soon
BOSTON — The myriad uses of ChatGPT and other large language models have spread like wildfire, but the two chief medical officers at the US Food and Drug Administration and the European Medicines Agency said yesterday that they aren’t about to start using the new tech to speed up drug reviews.
“I have one big concern and that’s garbage in, garbage out,” Steffen Thirstrup, CMO of EMA, told attendees at the Drug Information Association annual conference on Thursday. “These models only pick up what’s been published. That’s the tip of the iceberg.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.